Novo Nordisk celebrates 90 years of diabetes innovation

Global leader in diabetes care recognizes anniversary of Canadian roots 
MISSISSAUGA, ON, Feb. 19, 2013 /CNW/ - Danish-based pharmaceutical company 
Novo Nordisk is celebrating the 90(th) anniversary of when diabetes patients 
were first treated with the company's insulin. With its Canadian headquarters 
in Mississauga, the company is focused on developing new and better treatments 
for people with diabetes. Now the world's largest diabetes care company, Novo 
Nordisk provides therapeutic treatments for an estimated 23 million people 
with diabetes worldwide and produces approximately 50 per cent of all insulin 
in the world. 
Novo Nordisk's Canadian roots run deep and can be traced back to the 
University of Toronto, where Sir Frederick Banting and Charles Best first 
discovered insulin in 1921. In 1923, Nobel-prize winning physiologist Dr. 
August Krogh was granted permission from Banting and Best to produce insulin 
in Denmark, founding Nordisk Insulinlaboratorium - the company now known as 
Novo Nordisk. 
Since firmly establishing itself in Canada in 1983, Novo Nordisk has earned an 
enviable reputation for corporate achievement, emerging as Canada's market 
leading diabetes company. Novo Nordisk has been named among the fastest 
growing Top 20 Canadian research-based pharmaceutical companies, and has 
earned the distinction of being a Top Employer in the Greater Toronto Area. 
"Ninety years ago, our commitment to helping those living with diabetes began, 
shaping Novo Nordisk into the world leading diabetes company it is today," 
said Vince Lamanna, President, Novo Nordisk Canada Inc. "It is important to 
recognize and celebrate our roots as we move forward, striving for new 
innovations and advancements that help build a healthy future for Canadians, 
and people around the world." 
The beginning of Novo Nordisk
During a visit to the United States in 1922, Dr. August Krogh and his wife, 
Marie - a medical doctor living with diabetes - learned of the discovery of 
insulin in Canada. Marie urged her husband to meet with Professor John James 
Rickard Macleod at the University of Toronto, who was leading the team of 
researchers behind the discovery. August and Marie returned to Copenhagen in 
December 1922, bringing with them a desire to start insulin production in 
Scandinavia. A few months later, production was up and running and the first 
patients were treated at a hospital in Copenhagen. This was the beginning of 
what Novo Nordisk is today. 
Since then, the company has pioneered many important advances in diabetes 
treatment including human insulin (1982) and the world's first insulin pen, 
NovoPen(®) (1985). Later it developed several modern insulins (insulin 
analogues with improved properties) and is now also the leader in a new class 
of diabetes treatments - GLP-1 therapies. In parallel, Novo Nordisk has 
applied the skills it has built within diabetes on developing 
biopharmaceutical products for treatment of hemophilia, growth disorders and 
women's health. 
Novo Nordisk's largest shareholder is the Novo Nordisk Foundation, a Danish 
Foundation, which provides a stable basis for the company's activities and 
supports humanitarian and scientific purposes. 
Making a Difference 
At Novo Nordisk, patients are the priority. Novo Nordisk programs are making 
positive and lasting contributions in countries around the world, as well as 
right here in communities across Canada: 


    --  In 1994, Novo Nordisk becomes one of the first companies in the
        world to publish an environmental report.
    --  In 2002, Novo Nordisk founded the
        World Diabetes Foundation,
        which has grown into a leading international funding agency
        supporting grassroots initiatives in the area of diabetes
        prevention and care in the developing world.
    --  In 2005, Novo Nordisk partnered with the Ontario Physical and
        Health Education Association to teach kids about the importance
        of physical activity and healthy eating as a way to prevent
        diabetes.
    --  In 2006, Novo Nordisk joined the International Diabetes
        Federation and the Unite for Diabetes campaign to successfully
        pass a UN resolution recognizing World Diabetes Day.
    --  In 2006, Novo Nordisk is the tenth company in the world to join
        the World Wildlife Fund Climate Savers initiative, committing
        to reduce carbon emissions by 10 per cent by 2014.
    --  In 2007, the Changing Diabetes(®) world bus tour visits
        Canadian cities to raise awareness of diabetes.
    --  In 2008, Novo Nordisk partnered with JDRF Canada and the
        Canadian Diabetes Association to help Canadians mark World
        Diabetes Day, an important annual initiative that raises
        awareness of diabetes in communities across Canada and around
        the world.

About Diabetes in Canada
More than three million Canadians are living with diabetes, a number that is 
expected to increase reach 3.7 million by 2020.(1)

About Novo Nordisk Canada Inc.
Novo Nordisk is a healthcare company and a world leader in diabetes care and 
biopharmaceuticals. Novo Nordisk manufactures and markets pharmaceutical 
products and services that make a significant difference to patients, the 
medical profession and society. Novo Nordisk's business is driven by the 
Triple Bottom Line: a commitment to economic success, environmental soundness, 
and social responsibility to employees and customers. For more information, 
visit www.novonordisk.ca.

References 
_______________________
(1) Canadian Diabetes Association. "The prevalence and costs of diabetes." 
Accessed on February 8, 2013 at 
http://www.diabetes.ca/documents/about-diabetes/PrevalanceandCost_09.pdf.
    

Amanda Federchuk Consultant, GCI Group (416) 486-7231 
amanda.federchuk@gcicanada.com

 Jeremy Brace Manager, Corporate Relations (905) 629-6241 jmbc@novonordisk.com

SOURCE: Novo Nordisk Canada Inc.

To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/February2013/19/c6391.html

CO: Novo Nordisk Canada Inc.
ST: Ontario
NI: HEA MTC 

-0- Feb/19/2013 12:59 GMT